ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
GSK India delivered resilient FY26 results with double-digit EBITDA and PAT growth, despite muted 2% revenue growth due to significant supply disruptions from a CMO fire and vaccine shipment delays.
GSK reported muted 2% revenue growth due to supply chain disruptions at a key CMO, but delivered record-high EBITDA margins of 35% through cost optimization and a shift toward high-margin specialty products.
GSK India delivered strong Q1 FY27 standalone performance with revenue growing 15% and PAT up 24%, driven by portfolio transformation and core brand leadership.
GSK Pharma Q4 FY26 earnings call highlighting 2% revenue growth, 34% EBITDA margins, and a shift toward an innovation-led specialty portfolio.
GSK India delivered double-digit EBITDA and PAT growth for FY26 despite supply disruptions. Performance was bolstered by a transition toward high-margin specialty oncology and adult vaccines, compensating for a muted general medicine segment.
GSK India delivered a strong FY26 with 34.3% EBITDA margins and its first-ever PAT exceeding ₹1000 cr, driven by portfolio shifts toward high-growth Specialty and Innovative segments.